Is This Beaten-Down Artificial Intelligence (AI) Stock a Buy?
The artificial intelligence (AI) industry has been on a tear in the past two years, and judging by analyst estimates, it's just the beginning. AI-related sales will continue to soar in the coming years, so naturally, investors want to cash in by investing in those companies best positioned to profit from AI.Though many are attracted to corporations in the tech sector, it might be worth exploring other industries, including healthcare. Let's look at an AI-focused biotech company: Recursion Pharmaceuticals (NASDAQ: RXRX). The stock has significantly lagged the market in the past year, but if Recursion's ambitions become a reality, it could offer market-crushing returns from here on out.Is the stock a buy right now?Continue reading
The artificial intelligence (AI) industry has been on a tear in the past two years, and judging by analyst estimates, it's just the beginning. AI-related sales will continue to soar in the coming years, so naturally, investors want to cash in by investing in those companies best positioned to profit from AI.
Though many are attracted to corporations in the tech sector, it might be worth exploring other industries, including healthcare. Let's look at an AI-focused biotech company: Recursion Pharmaceuticals (NASDAQ: RXRX). The stock has significantly lagged the market in the past year, but if Recursion's ambitions become a reality, it could offer market-crushing returns from here on out.
Is the stock a buy right now?
